HOME >> MEDICINE >> NEWS
Phase II trial of anthrax vaccine to begin

Center for Vaccine Research needs volunteers for Phase II Trial of anthrax vaccine candidate

(Torrance, CA April 22, 2004) The UCLA Center for Vaccine Research, a leading research program at the Research and Education Institute (REI) at Harbor UCLA Medical Center, announced today that it has initiated a Phase II trial of a new anthrax vaccine, rPA102 (VaxGen, Inc.). The 13-month trial is taking place at 12 medical centers in the United States and is one of two studies of rPA102 initiated this year under a multi-year, $80.3 million U.S. government contract to VaxGen, Inc. from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

VaxGen, Inc. began developing rPA102 to address the need for an anthrax vaccine that has an improved safety profile and a more practical dosing schedule compared to the existing licensed anthrax vaccine. rPA is a synthetic protein vaccine that induces antibodies that are designed to prevent illness by neutralizing anthrax toxins. rPA102 cannot cause anthrax infection. The goal of this study is to determine the optimal formulation of the rPA vaccine that will provide an early and protective immune response.

Healthy adults, 18 to 55 years of age, who have not received an anthrax vaccine and have not been exposed to anthrax, are needed to participate in this study. Participants will need to be available for 14 visits to the clinic (Torrance) over a one-year period. Participants will be compensated up to $700 for completion of study visits.

For further information on how to take part in this trial, please call 1-800-637-8860.


'"/>

Contact: Susan Partridge, BSN, MBA
partridge@humc.edu
310-781-3630
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
22-Apr-2004


Page: 1

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
3. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
4. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
5. Penn researchers announce results of Phase I trial using combretastatin drug
6. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
9. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
10. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
11. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... July 03, 2020 , ... ... with memory impairment, has announced the Best Memory Care Facilities in Charleston, South ... experts, facility features and amenities. , According to the Alzheimer’s Association ...
(Date:7/2/2020)... Conn. (PRWEB) , ... July 02, 2020 , ... ... of many businesses, including dental offices for non-emergency work. In conjunction with the ... reopening guidelines for Connecticut dental practices in mid-May. , Due to safety ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... today that it has been selected by Codiak BioSciences to support its cleanroom ... will provide the cleanroom infrastructure for the drug substance and product manufacturing for ...
(Date:6/28/2020)... ... 26, 2020 , ... The Coronavirus pandemic created shortages in ... supplier of top-quality masks, sanitizers and thermometers, Trusted PPE is a woman and ... observed, “All of our masks are manufactured to medical standards in FDA-certified factories, ...
(Date:6/25/2020)... ANNAPOLIS, Md. (PRWEB) , ... June 25, 2020 , ... ... and treating providers on the key steps when filing appeals for denials of mental ... insurance experts to help educate individuals about their appeal rights and explain the steps ...
Breaking Medicine News(10 mins):
(Date:6/25/2020)... ... 2020 , ... NeoTract, a wholly owned subsidiary of Teleflex ... announced that Tarek Pacha, D.O., Memorial Heathcare in Owosso, MI, has been designated ... achieved a high level of training and experience with the UroLift® System and ...
(Date:6/25/2020)... , ... June 25, 2020 , ... ... Connecticut Magazine’s 2020 Top Dentist list within the Periodontics category. As specialists, this ... in New London, CT and Westerly, RI. Laser gum disease therapy, minimally invasive ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... DisasterReady.org to launch one of the first online COVID-19 trainings for health ... eight courses in this free training entitled COVID-19 Training for Health Workers: ...
Breaking Medicine Technology:
Cached News: